UT Southwestern scientist awarded prestigious American Cancer Society research professorship

October 21, 2003

DALLAS - Oct. 21, 2003 - Dr. Luis Parada, director of the Center for Developmental Biology at UT Southwestern Medical Center at Dallas, has been awarded this year's only American Cancer Society basic research professorship, making him one of 20 such designated professors nationwide.

The research professorship carries a five-year award of $60,000 per year with the possibility of a five-year renewal. It was announced at the American Cancer Society's Research Council for Extramural Grants recent meeting and becomes effective Jan. 1, 2004.

The ACS Professorships provide flexible funding for established full-time investigators in mid-career who have made novel or watershed contributions to cancer research and are expected to continue to provide leadership in their research areas. The American Cancer Society grants no more than two basic research professorships and two clinical research professorships a year.

"This is a great honor because there are very few of these professorships, and every ACS Research Professor I know is an accomplished scientist," said Dr. Parada, director of the Kent Waldrep Center for Basic Research on Nerve Growth and Regeneration. "It gives me an additional degree of freedom in my research, and, aside from the personal honor, it will help enhance the visibility of cancer research at UT Southwestern."

Dr. John Stevens, the American Cancer Society's vice president for extramural grants, said: "In awarding Dr. Parada this professorship, the society recognizes his extraordinary ability to integrate the fields of molecular genetics, embryonic development and signal transduction in ways that will provide critical insights into how brain cancers arise, develop and progress, thus paving the way to better treatments for these devastating tumors.

"This is the most prestigious grant awarded by the society and the only one that carries the society's name. Dr. Parada is highly regarded for several groundbreaking contributions to the understanding of brain development and basic biology of the cancer cell."

Funding is limited to 10 years, but Dr. Parada can use the title of American Cancer Society Research Professor during the remainder of his career.

"The ACS Research Professorship award brings recognition to Dr. Parada and the quality of basic research being done at UT Southwestern," said Dr. Kern Wildenthal, UT Southwestern president. "Luis is one of our most influential and respected research leaders, and we are extremely pleased at this national recognition for his work."

Dr. Parada and his colleagues are also working to understand why, after initial development of the body is complete, it cannot repair damaged nerve tissue in the same way as other tissues can, like the skin.

Dr. Parada graduated with honors from the University of Wisconsin, Madison, with a bachelor's degree in molecular biology. He completed his doctorate in biology at the Massachusetts Institute of Technology and served postdoctoral fellowships at the Whitehead Institute in Cambridge, Mass., and at the Pasteur Institute in Paris.

Dr. Parada is the second UT Southwestern faculty member to receive an ACS Professorship. Dr. Barton Kamen, a former professor of pediatrics and pharmacology, received the ACS Clinical Research Professorship award in 1994.
This news release is available on our World Wide Web home page at http://irweb.swmed.edu/newspub/newsdetl.asp?story_id=672

To automatically receive news releases from UT Southwestern via e-mail, subscribe at http://lists.utsouthwestern.edu/mailman/listinfo/utswnews

UT Southwestern Medical Center

Related Cancer Research Articles from Brightsurf:

As cancer has evolved, it is time for cancer research to do the same
Marking Lung Cancer Awareness month, a new study investigates the extent to which human-based, non-animal approaches are supplanting animal models in cancer research - comparing number of publications, funding, and publications associated with clinical trials between xenograft models and human organoids.

New liver cancer research targets non-cancer cells to blunt tumor growth
'Senotherapy,' a treatment that uses small molecule drugs to target ''senescent'' cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.

Blueprint to beat cancer launched today by World Cancer Research Fund (WCRF)
Overweight and obesity increase cancer risk. A new report published today by World Cancer Research Fund (WCRF), and presented at the European Congress on Obesity in Vienna, shows that overweight or obesity is a cause of at least 12 cancers, five more than WCRF findings a decade ago.

Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.

UA Cancer Center research team explores anti-breast cancer properties of soy
Genistein, a major compound in soy foods, might aid in the proper functioning of a gene that can malfunction to cause breast cancer.

Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.

The potential consequences for cancer care and cancer research of Brexit
Cancer leaders highlight main fears for patient care, treatment and research in a post-Brexit world.

Cancer Research UK announces Grand Challenge teams to answer biggest questions in cancer
Cancer Research UK today announces that four international teams are the first recipients of its global £100 million Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.

Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.

Leading cancer research organizations to host cancer immunotherapy conference
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will sponsor the second International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel (811 7th Ave., New York, NY 10019) and the New York Hilton Midtown ( 1335 Avenue of the Americas, New York, NY 10019), Sept.

Read More: Cancer Research News and Cancer Research Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.